Form 4: Janux Therapeutics Director Reports Equity Grants Held for RA Capital Funds, Disclaims Personal Ownership

Janux Therapeutics Director Jake Simson reported the grant of 3,750 restricted stock units and 11,667 stock options, which he holds for the benefit of RA Capital Management funds, disclaiming personal beneficial ownership.

Summary

• Jake Simson, a Director of Janux Therapeutics, Inc. (JANX), reported new equity grants on June 11, 2025.
• He was granted 3,750 Restricted Stock Units (RSUs) at a price of $0.
• He was also granted 11,667 stock options with an exercise price of $25.46.
• The RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.
• The stock options will vest in equal monthly installments over 12 months following June 11, 2025, or fully vest on the date of the next annual meeting, subject to continuous service.
• Mr. Simson holds these securities for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and explicitly disclaims personal beneficial ownership.
• He is obligated to turn over any net cash or stock received from these securities to RA Capital Management, L.P., which will offset advisory fees owed by the aforementioned funds.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of equity incentives is generally positive for aligning interests, but the disclaimed beneficial ownership by the individual director makes it less directly impactful for personal incentive alignment, though it serves the purpose for the associated funds.

Positives

• The grant of equity incentives (RSUs and stock options) to a director, even if indirectly held, can align interests with the company's performance and long-term strategy.
• The transaction is a routine disclosure, indicating transparency in insider compensation arrangements.

Negatives

• The director's disclaimer of personal beneficial ownership means these grants do not directly incentivize the individual director's personal financial gain, which might dilute the typical alignment effect of such grants.

Risks

• Potential minor dilution from the future exercise of stock options and settlement of RSUs, although the reported amounts are relatively small.
• The unique structure where the director disclaims beneficial ownership might introduce complexity regarding the direct incentive alignment for the individual director.

Future Outlook

The document details future vesting schedules for the granted RSUs and stock options, with vesting contingent on continuous service and tied to specific future dates or the next annual meeting of stockholders.

Management Comments

• "The Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. and the RA Capital Nexus Fund II, L.P."
• "The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor."
• "The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."

Industry Context

This Form 4 filing is a routine disclosure of insider equity grants, common in the biotechnology and pharmaceutical sectors (where Janux Therapeutics operates) to incentivize directors and align their interests with shareholders. The specific arrangement with RA Capital Management, where the director disclaims personal beneficial ownership, is less common for individual director grants but reflects a specific investment fund's governance structure.

Comparison to Industry Standards

• The grant of RSUs and stock options to directors is a standard practice in the biotechnology industry for compensation and incentive alignment.
• The specific arrangement where the director disclaims beneficial ownership and holds the securities for the benefit of an investment fund (RA Capital Management) is a unique aspect of this grant, differing from typical direct personal ownership by directors in comparable biotech companies.

Related Party Transactions

• The reporting person, Jake Simson, holds the granted stock options and RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., which are funds managed by RA Capital Management, L.P. (the "Advisor").
• Mr. Simson is obligated to turn over any net cash or stock received from these securities to the Advisor, which will offset advisory fees owed by the funds to the Advisor.

Stakeholder Impact

• Shareholders: Potential minor dilution from future exercise/settlement of equity grants. The grants are part of director compensation, which is a routine cost. Shareholders invested in RA Capital Management's funds may find the specific arrangement relevant to their investment structure.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Vesting of 3,750 Restricted Stock Units (RSUs) on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders.
• Monthly vesting of 11,667 stock options over 12 months following June 11, 2025, or full vesting on the date of the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, RA Capital Management